Literature DB >> 11163542

Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain.

A Urakubo1, L F Jarskog, J A Lieberman, J H Gilmore.   

Abstract

Prenatal exposure to infection appears to increase the risk of schizophrenia and other neurodevelopmental disorders. We have hypothesized that cytokines, generated in response to maternal infection, play a key mechanistic role in this association. E16 timed pregnancy rats were injected i.p. with Escherichia coli lipopolysaccharide (LPS) to model prenatal exposure to infection. Placenta, amniotic fluid and fetal brains were collected 2 and 8h after LPS exposure. There was a significant treatment effect of low-dose (0.5mg/kg) LPS on placenta cytokine levels, with significant increases of interleukin (IL)-1beta (P<0.0001), IL-6 (P<0.0001), and tumor necrosis factor-alpha (TNF-alpha) (P=0.0001) over the 2 and 8h time course. In amniotic fluid, there was a significant effect of treatment on IL-6 levels (P=0.0006). Two hours after maternal administration of high-dose (2.5mg/kg) LPS, there were significant elevations of placenta IL-6 (P<0.0001), TNF-alpha (P<0.0001), a significant increase of TNF-alpha in amniotic fluid (P=0.008), and a small but significant decrease in TNF-alpha (P=0.035) in fetal brain. Maternal exposure to infection alters pro-inflammatory cytokine levels in the fetal environment, which may have a significant impact on the developing brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11163542     DOI: 10.1016/s0920-9964(00)00032-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  118 in total

Review 1.  The maternal-neonatal neuro-immune interface: are there long-term implications for inflammatory or stress-related disease?

Authors:  N Shanks; S L Lightman
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  NATURAL ANTIMICROBIALS AND THEIR ROLE IN VAGINAL HEALTH: A SHORT REVIEW.

Authors:  S E Dover; A A Aroutcheva; S Faro; M L Chikindas
Journal:  Int J Probiotics Prebiotics       Date:  2008

Review 3.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

4.  Maternal immune activation by LPS selectively alters specific gene expression profiles of interneuron migration and oxidative stress in the fetus without triggering a fetal immune response.

Authors:  Devon B Oskvig; Abdel G Elkahloun; Kory R Johnson; Terry M Phillips; Miles Herkenham
Journal:  Brain Behav Immun       Date:  2012-01-30       Impact factor: 7.217

5.  Placental microRNA expression in pregnancies complicated by preeclampsia.

Authors:  Daniel A Enquobahrie; Dejene F Abetew; Tanya K Sorensen; David Willoughby; Kumaravel Chidambaram; Michelle A Williams
Journal:  Am J Obstet Gynecol       Date:  2010-11-20       Impact factor: 8.661

Review 6.  Potential microbial origins of schizophrenia and their treatments.

Authors:  S Hossein Fatemi
Journal:  Drugs Today (Barc)       Date:  2009-04       Impact factor: 2.245

Review 7.  A review of the fetal brain cytokine imbalance hypothesis of schizophrenia.

Authors:  Urs Meyer; Joram Feldon; Benjamin K Yee
Journal:  Schizophr Bull       Date:  2008-04-11       Impact factor: 9.306

8.  Toll-like receptor 4-mediated immune stress in pregnant rats activates STAT3 in the fetal brain: role of interleukin-6.

Authors:  Abdeslam Mouihate; Heba Mehdawi
Journal:  Pediatr Res       Date:  2015-05-04       Impact factor: 3.756

9.  Interleukin-1 mediates long-term hippocampal dentate granule cell loss following postnatal viral infection.

Authors:  Anna G Orr; Anup Sharma; Nikolaus B Binder; Andrew H Miller; Bradley D Pearce
Journal:  J Mol Neurosci       Date:  2009-09-23       Impact factor: 3.444

Review 10.  Understanding and determining the etiology of autism.

Authors:  Salvatore A Currenti
Journal:  Cell Mol Neurobiol       Date:  2009-09-23       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.